An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Completed
Parexel
Phase 3
2011-04-01
NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of
netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with
oral dexamethasone. The objective of the study is to demonstrate that netupitant and
palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting
induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles
of chemotherapy.
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Completed
Helsinn Healthcare SA
Phase 3
2011-04-01
NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of
netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with
oral dexamethasone. The objective of the study is to demonstrate that netupitant and
palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting
induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles
of chemotherapy.
A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Completed
Parexel
Phase 3
2011-07-01
NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two
antiemetic drugs, both given with oral dexamethasone. The objective of the study is to
evaluate if netupitant and palonosetron are safe when administered to prevent nausea and
vomiting after administration of repeated cycles of chemotherapy.
A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Completed
Helsinn Healthcare SA
Phase 3
2011-07-01
NETU-10-29 is a clinical study assessing safety of netupitant and palonosetron, two
antiemetic drugs, both given with oral dexamethasone. The objective of the study is to
evaluate if netupitant and palonosetron are safe when administered to prevent nausea and
vomiting after administration of repeated cycles of chemotherapy.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
